"José Mataix" Institute of Nutrition and Food Technology, Biomedical Research Centre, Health Sciences Technological Park, University of Granada, 18016, Armilla, Granada, Spain.
Department of Biochemistry and Molecular Biology II, University of Granada, 18016, Armilla, Granada, Spain.
Eur J Nutr. 2019 Apr;58(3):1203-1211. doi: 10.1007/s00394-018-1638-9. Epub 2018 Feb 21.
The main objective of this study was to test the therapeutic potential of hydroxytyrosol and its combination with paclitaxel in breast cancer on oxidative stress status.
Impact on proliferation rates of different chemotherapy administration patterns was assayed in MCF-7 and MDA-MB-231 breast cancer cell lines. Breast tumor-bearing rats were randomly assigned to Control, Hydroxytyrosol, Paclitaxel and Paclitaxel plus hydroxytyrosol groups, for 6 weeks. Tumor volume, cell proliferation and several systemic oxidative stress parameters were measured. Anti-proliferative activity in vitro experiments was correlated with in vivo experiments.
Combination group did significantly reduce tumor volume when compared with paclitaxel alone. Additionally, the combination improved the antioxidant status without compromising the antitumor activity of standard chemotherapy.
These findings reveal for the first time that hydroxytyrosol is an active partner in combined therapies with paclitaxel against breast cancer. Combination with hydroxytyrosol would also ensure a less oxidative impact of chemotherapeutic drugs that could potentially improve patient wellness.
本研究的主要目的是测试羟基酪醇及其与紫杉醇联合治疗乳腺癌对氧化应激状态的治疗潜力。
在 MCF-7 和 MDA-MB-231 乳腺癌细胞系中检测不同化疗给药模式对增殖率的影响。将荷瘤大鼠随机分为对照组、羟基酪醇组、紫杉醇组和紫杉醇加羟基酪醇组，治疗 6 周。测量肿瘤体积、细胞增殖和几种全身氧化应激参数。体外实验的抗增殖活性与体内实验相关联。
与单独紫杉醇相比，联合组显著降低了肿瘤体积。此外，该联合治疗改善了抗氧化状态，同时不影响标准化疗的抗肿瘤活性。
这些发现首次揭示，羟基酪醇是与紫杉醇联合治疗乳腺癌的有效伙伴。与羟基酪醇联合使用还可以确保化疗药物的氧化影响更小，从而有可能提高患者的健康水平。
